Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30360171 | 1.00 | EPAS1 (0.41) | EPAS1L3MBTL1ALDH1A1PKMMAPK1 | |
| SCHEMBL14524889 | 0.97 | EPAS1 (0.40) | EPAS1L3MBTL1ALDH1A1PKMMAPK1 | |
| SCHEMBL24966444 | 0.93 | L3MBTL1 (0.38) | EPAS1L3MBTL1ALDH1A1PKMMBTD1 | |
| SCHEMBL942322 | 0.93 | L3MBTL1 (0.38) | EPAS1L3MBTL1ALDH1A1PKMMBTD1 | |
| SCHEMBL5682444 | 0.93 | L3MBTL1 (0.38) | EPAS1L3MBTL1ALDH1A1PKMMAPK1 | |
| SCHEMBL3094274 | 0.90 | ALDH1A1 (0.39) | EPAS1L3MBTL1ALDH1A1PKMMAPK1 | |
| SCHEMBL18501167 | 0.90 | L3MBTL1 (0.36) | EPAS1L3MBTL1ALDH1A1PKMGRIN1 | |
| SCHEMBL29895427 | 0.90 | L3MBTL1 (0.36) | EPAS1L3MBTL1ALDH1A1PKMMAPK1 | |
| SCHEMBL10622966 | 0.90 | L3MBTL1 (0.36) | EPAS1L3MBTL1ALDH1A1PKMMAPK1 | |
| SCHEMBL18526481 | 0.90 | ALDH1A1 (0.39) | EPAS1L3MBTL1ALDH1A1PKMMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11529359-B2 | Use of GABAA receptor modulators for treatment of itch | UNIVERSITAT ZURICH (CH) | 2022-12-20 | — | — | US | disclosed |
| US-20220152037-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF PAIN | NEUROCYCLE THERAPEUTICS, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20210100814-A1 | Use of GABAA receptor modulators for treatment of itch | UNIVERSITAT ZURICH (CH) | 2021-04-08 | — | — | US | disclosed |
| US-10836688-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200148610-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | ABBVIE INC. | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148610-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | LIPA, ALG1, CEL | EPAS1 4543/4885L3MBTL1 3610/4885ALDH1A1 1595/4885 |
| US-10836688-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | LIPA, ALG1, CEL | EPAS1 4543/4885L3MBTL1 3610/4885ALDH1A1 1595/4885 |
| US-20210100814-A1 | Use of GABAA receptor modulators for treatment of itch | GABRB2, GABRB3, GABRB1 | EPAS1 3572/4885L3MBTL1 4698/4885ALDH1A1 996/4885 |
| US-11529359-B2 | Use of GABAA receptor modulators for treatment of itch | GABRB2, GABRB3, GABRB1 | EPAS1 3572/4885L3MBTL1 4698/4885ALDH1A1 996/4885 |
| US-20220152037-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF PAIN | GABRB2, GABRB1, GABBR1 | EPAS1 2850/4885L3MBTL1 4756/4885ALDH1A1 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.